Answers are grounded in this paper and cite their sources.
Hematopoietic stem cell transplantation (HSCT) can rescue B-cell acute lymphoblastic leukemia (B-ALL) recurring after CD19-directed chimeric antigen receptor T cells (CAR19 T cells). However, in patients at high risk of relapse, the indication for and timing of consolidative HSCT are controversial. We retrieved data on 112 patients who received an HSCT at a median of 6.1 months after CAR19 T-cell infusion. Indication for subsequent HSCT were: (I) Rescue in 72 (64%) patients for disease recurrence; (II) Pre-emptive in 21 (19%) for loss of B-cell aplasia; (III) Consolidative in 19 patients (17%). The 2-year post-transplant Leukemia-Free Survival (LFS) was 54% and the 2-year cumulative incidence of relapse was 32%. Children had better LFS than adults (63% vs 38%). Older age was associated with inferior LFS (HR per 10-year increase 1.30; p= 0.01) and patients receiving a rescue HSCT had a significantly lower 2-year LFS (41%), compared to pre-emptive (74%) and consolidative HSCT (78%), respectively (p=0.002). Haploidentical donor was also associated with inferior LFS (HR: 2.21 95%CI: 1.15-4.25, p=0.02). This "real-world" study corroborates the need to identify patients at higher risk of relapse and optimization of strategies to improve outcome in patients with R/R B-ALL receiving CD19-directed CAR T cells.
No takes yet. Share an insight, caveat, or question.
Ottaviano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: